A common solution to group 2 influenza virus neutralization

The discovery and characterization of broadly neutralizing antibodies (bnAbs) against influenza viruses have raised hopes for the development of monoclonal antibody (mAb)-based immunotherapy and the design of universal influenza vaccines. Only one human bnAb (CR8020) specifically recognizing group 2...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Friesen, Robert H. E., Lee, Peter S., Stoop, Esther J. M., Hoffman, Ryan M. B., Ekiert, Damian C., Bhabha, Gira, Yu, Wenli, Juraszek, Jarek, Koudstaal, Wouter, Jongeneelen, Mandy, Korse, Hans J. W. M., Ophorst, Carla, Brinkman-van der Linden, Els C. M., Throsby, Mark, Kwakkenbos, Mark J., Bakker, Arjen Q., Beaumont, Tim, Spits, Hergen, Kwaks, Ted, Vogels, Ronald, Ward, Andrew B., Goudsmit, Jaap, Wilson, Ian A.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2014
Assuntos:
Biological Sciences
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3890827/
https://ncbi.nlm.nih.gov/pubmed/24335589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1319058110
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados